Merck’s Capvaxive shows strong momentum amid industry vaccine decline
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Subscribe To Our Newsletter & Stay Updated